Logo

Devyser HBOC Kit for Hereditary Breast, Ovarian Cancer Testing

Nov 27, 2019

Swedish genetic test developer Devyser has launched the HBOC kit for hereditary breast and ovarian cancer testing. The kit is based on Devyser's proprietary next-generation sequencing library prep technology, and provides targeted sequencing of 12 genes in which mutations are associated with an increased risk of developing breast and ovarian cancer. The company said that the workflow takes less than 45 minutes. The HBOC kit is part of Devyser's NGS Oncology suite, complementing the company's BRCA kit that enables simultaneous screening of mutations in the BRCA1 and BRCA2 genes. The new kit is available in the EU and through Devyser distributors in several countries in the Middle East, Southeast Asia, China, South America, and Africa. Customers in countries in which Devyser does not have distributors currently (e.g. the US and Canada) can self-import the assay, a company spokesperson said.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.